Abstract
Recent studies have identified microbial components in most tumors and invoked microorganisms in cancer onset and progression. The microbial functions responsible for these effects likely include production of genotoxins, modification of human gene expression, and protection of cancer cells from immune surveillance. Metatranscriptomics (MT) is a powerful tool for the development of potential cancer diagnostics and therapeutics, as well as investigating cancer initiation and progression. This is because MT data can quantify human and microbial gene expression, as well as provide strain level taxonomic classification of the microorganisms in the tumor microenvironment (TME). In addition, the microbial data derived from the MT method can easily be normalized across different samples, since many human transcripts can act as internal standards. When collecting tissue samples for clinical studies, researchers have the option of using fresh or Formalin-Fixed Paraffin-Embedded (FFPE) samples. FFPE samples are much easier to study, due to their widespread availability and ease of collection, storage, and handling. Little research exists comparing FFPE samples and fresh tissues, and there is no literature examining the differences in microbial signatures between these two sample preservation methods. In this study, we analyzed matched FFPE samples and fresh tissue samples from colon polyps of 13 participants for microbial and human components. We found that our clinically validated MT method generated equivalent data from FFPE samples and fresh tissue samples with high concordance for human gene expression (Pearson 0.70), microbial species (Pearson 0.94), and KEGG Orthologs (Pearson 0.97). These data indicate that FFPE samples are suitable for use in metatranscriptomic analyses, which will enable more diverse and larger oncology studies, as well as any other studies that benefit from MT analysis of tissue samples.
Competing Interest Statement
All authors are either employees or paid advisors of Viome Life Sciences, Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Funding Statement
Viome Life Sciences
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Viome IRB of Viome Life Sciences gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are proprietary to Viome Life Sciences but may be available upon reasonable request to the authors
